Skip to main content

Intracellular Signaling Triggered by Formyl-Peptide Receptors in Nonphagocytic Cells

Buy Article:

$68.00 + tax (Refund Policy)

Formyl-peptide receptors (FPR) are expressed in several cell types including phagocytic leukocytes, and a wide variety of agonists of FPR and of its FPRL1 variant have been identified. These ligands interact with their specific receptors on the cellular membrane, and activate specific biological functions through a G-protein-coupled pathway. In nonphagocytic cells, agonist/FPR binding also induces transactivation of the constitutive membrane receptors PDGF-R, EGF-R and uPAR that in turn trigger specific, characteristic intracellular signal transduction pathways. The second messengers resulting from the interaction between ligands and formyl-peptide receptors act on various intracellular kinases (mitogen-activated protein kinases, protein kinases C and B, Jun kinase and some tyrosine kinases). Activation of NADPH oxidase expressed in nonphagocytic cells, and phosphorylation and nuclear translocation of regulatory transcriptional factors may be the downstream targets of this signaling cascade. The activated signal transduction pathways also lead to various biochemical cellular responses that can contribute to cell proliferation, and can protect against cell death and the malignant behavior of several human cancer cell lines. Dissection of the signaling cascade triggered by different agonists will shed light on the role of FPRs in nonphagocytic cells in both human physiology and diseases.





Keywords: Formyl-peptide receptors; NADPH oxidase; kinases; nonphagocytic cells; reactive oxygen species; transduction signals

Document Type: Research Article

Publication date: 01 May 2008

More about this publication?
  • In recent years a breakthrough has occurred in our understanding of the molecular pathomechanisms of human diseases whereby most of our diseases are related to intra and intercellular communication disorders. The concept of signal transduction therapy has got into the front line of modern drug research, and a multidisciplinary approach is being used to identify and treat signaling disorders.

    The aim of this journal is to publish timely in-depth reviews as well as original papers in the field of signal transduction therapy. Thematic issues will also be published to cover selected areas of signal transduction therapy. Coverage of the field will include genomics, proteomics, medicinal chemistry and the relevant diseases involved in signaling e.g. cancer, neurodegenerative and inflammatory diseases.

    Current Signal Transduction Therapy is an essential journal for all involved in drug design and discovery.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content